Navigation Links
ImmuneRegen BioSciences, Inc. Demonstrates Radilex(TM) Increases Disease-Fighting White Blood Cells
Date:8/27/2007

those caused by influenza virus), autoimmune disorders, certain medications (including most cytotoxic chemotherapy), radiation and bone marrow diseases such as leukemia or myelodysplastic syndromes. Replenishment of leukocytes at early time periods following irradiation could result from proliferation and maturation of a pluripotential stem cell subset that is protected from the damaging effect of radiation. Further studies are in process to delineate the mechanism of leukocyte replenishment.

About TGen

The Translational Genomics Research Institute (TGen), a non-profit 501(c)(3) organization, is focused on developing earlier diagnostics and smarter treatments. Translational genomics research is a relatively new field employing innovative advances arising from the Human Genome Project and applying them to the development of diagnostics, prognostics and therapies for cancer, neurological disorders, diabetes and other complex diseases. TGen's research is based on personalized medicine and the institute plans to accomplish its goals through robust and disease-focused research.

About Radilex(TM) and Viprovex(R)

Radilex(TM) is the trade name used in referring to formulations of Homspera(TM) for potential indications for treatment of exposure to ionizing radiation. Viprovex(R) is the trade name used in referring to formulations of Homspera(TM) for potential indications for treatment of viral and bacterial infections. Homspera(TM) is a generic name used by the Company to describe the synthetic peptide Sar9, Met (O2)11-Substance P. Sar9, Met (O2)11-Substance P is an analog of the naturally occurring human neuropeptide Substance P, which can be found throughout the body, including in the airways of humans and many other species. All of the Company's research and development efforts are early, pre-clinical stage and Homspera(TM), as Viprovex(R) and Radilex(TM), has only undergone exploratory studies to evaluate its biological activity in small animals.<
'/>"/>

SOURCE ImmuneRegen BioSciences, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. ImmuneRegen BioSciences Announces Promising Data on Homspera Suggesting Potential as a Co-Therapeutic Agent
2. Ace Biosciences, Ace393, the Worlds First Commercial Vaccine for Travellers Diarrhoea Caused by Campylobacter Successfully Completes Phase I Clinical Trials
3. The International Myeloma Foundation Says Data Reported at a Global Medical Meeting in Greece Demonstrates Improved Survival for a Wide Range of Myeloma Patients
4. Publication on Pixantrone Preclinical Studies Demonstrates Reduced Cardiotoxicity Compared to Equiactive Doses of Doxorubicin and Mitoxantrone
5. New Research Demonstrates Broad Efficacy of Azixa (MPC-6827) Against Multiple Tumor Types and in Drug Resistant Cell Lines
6. Algeta Demonstrates Targeted Cancer-killing Potential of Novel Alpha Particle Linked Antibodies in Leading Medical Journal Blood
7. Gerons Telomerase Inhibitor Cancer Drug Demonstrates Good Pharmacokinetics and Tolerability in Phase I/II Trial
8. Frova Phase III Study Data Demonstrates That Short-Term Prevention Treatment Reduces Frequency and Severity of Menstrual Migraine
9. Mymetics HIV Vaccine Demonstrates First-Ever Production of Neutralizing IgA Antibodies in Non-Human Primate Model
10. Cipralex demonstrates superiority to duloxetine for acute treatment of depression in new study
11. Newly Published Data Demonstrates Superiority of Cipralex Over Duloxetine for Acute Treatment of Depression
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... , Nov. 25, 2014  Unilife Corporation (NASDAQ: UNIS, ... drug delivery systems, today announced that its Chairman and ... at the Piper Jaffray 26th Annual Healthcare Conference at ... on Tuesday, December 2, 2014. The ... a "live" listen only Webcast. To listen, please go ...
(Date:11/26/2014)... and LONDON , Nov. 25, 2014 ... (NYSE: AZN ) today announced that AMAGINE-2 TM ... of brodalumab in more than 1,800 patients with moderate-to-severe plaque ... ® (ustekinumab) and placebo at week 12. Brodalumab 210 ... group were each shown to be superior to Stelara on ...
(Date:11/26/2014)... , Nov. 25, 2014 Halozyme Therapeutics, Inc. (NASDAQ: ... Jaffray Healthcare Conference in New York ... PDT . Dr. Helen Torley , President and ... The presentation will be webcast through the "Investors" section of ... will be made available for 90 days following the event. ...
Breaking Medicine Technology:Unilife to Present at the Piper Jaffray 26th Annual Healthcare Conference on December 2nd 2Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 2Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 3Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 4Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 5Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 6Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 7Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 8Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 9Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 10Halozyme Therapeutics To Present At The Piper Jaffray Healthcare Conference 2
... 10, 2011 Nephros, Inc. (OTC Bulletin Board: ... by the Food and Drug Administration ("FDA") of the 510(k) ... On August 11, 2011 Nephros submitted a new 510(k) ... disease.  On November 8, 2011 Nephros received the initial FDA ...
... N.C., Nov. 10, 2011 Max Healthcare, India,s first ... today announced organizational changes that include Dr. Ajay Bakshi ... 1, 2011. The Company also named Dr. Abha Aggarwal ... that Mr. Ranvir Bhandari would be taking the additional ...
Cached Medicine Technology:Nephros Receives Initial FDA Response to 510(k) Application for Hemodiafiltration System 2Nephros Receives Initial FDA Response to 510(k) Application for Hemodiafiltration System 3Nephros Receives Initial FDA Response to 510(k) Application for Hemodiafiltration System 4Max Healthcare Announces Organizational Changes 2
(Date:11/27/2014)... In order to enable people to adapt ... an easy way to avoid touching a toilet seat and/or ... a prototype of the patent-pending Toilet Tamer, a device that ... and/or lid in a more sanitary manner. It avoids direct ... Overall, it promotes good hygiene and peace of mind. The ...
(Date:11/27/2014)... November 27, 2014 Two international trainers ... procedure will help one person with significant needs ... Saj Jivraj and Dr. Mamaly Reshad of the Anacapa ... have launched a website devoted to helping dentist learn ... the website would be devoted to helping a patient ...
(Date:11/27/2014)... 27, 2014 Dr. Ronald Receveur, who has ... a few oral health tips before patients dig into the ... and New Albany affordable cosmetic dentistry, and his ... starch and sugar. While the staff wishes everyone a happy ... for how patients can enjoy a feast that is also ...
(Date:11/27/2014)... The Little Gym, we know that being active provides ... a recent study confirmed that regular physical activity can ... Pediatrics found that “Promoting physical activity that involves ... may be important not only for health, but also ... of children; those that were engaging in regular physical ...
(Date:11/27/2014)... Ethane Web Technologies, an ISO 9001: 2008 certified ... Christmas discount on PPC service. The discount will be available ... begin on 1 December 2014 and remain valid until midnight ... PPC professional working at Ethane Web Technologies says, "This is ... this big discount would make the service quite affordable for ...
Breaking Medicine News(10 mins):Health News:World-Renowned Oxnard All-on-4™ Dental Implants Experts to Give Away Full Mouth Rehabilitation Annually 2Health News:World-Renowned Oxnard All-on-4™ Dental Implants Experts to Give Away Full Mouth Rehabilitation Annually 3Health News:World-Renowned Oxnard All-on-4™ Dental Implants Experts to Give Away Full Mouth Rehabilitation Annually 4Health News:World-Renowned Oxnard All-on-4™ Dental Implants Experts to Give Away Full Mouth Rehabilitation Annually 5Health News:New Albany Dental Practice Offers Oral Health Tips For Thanksgiving 2Health News:New Albany Dental Practice Offers Oral Health Tips For Thanksgiving 3Health News:New Albany Dental Practice Offers Oral Health Tips For Thanksgiving 4Health News:Ethane Web Technologies Announces 10% Christmas Discount on PPC Service 2
... speaks to you, do you see what they are saying? ... hear, but recent studies suggest that we use a variety ... speech as something we hear, see and even feel. In ... , a journal of the Association for Psychological Science, psychologist ...
... quality care at Cancer Treatment Centers of America ... of America (CTCA) has opened the nation,s first ... facility is the fourth hospital in the steadily ... Medical Center (Western) extends the comprehensive electronic health ...
... 11 /PRNewswire-USNewswire/ -- The U.S. House of ... Assisted Living Federation of America to help law ... Alert Act (H.R. 632), authored by Congressman Lloyd ... vote."We commend Congressman Doggett for his leadership. This ...
... enable more time for direct resident care, ... increase staff satisfactionPITTSBURGH, Feb. 11 Vocollect ... Partners Management Group (Preferred Care) headquartered in ... in two of its managed skilled nursing ...
... efficacy a building block for health reformWASHINGTON, Feb. ... America,s Health Insurance Plans (AHIP), today issued the ... in the Senate-passed stimulus bill:"At a time when ... serious concern for many Americans, it is critical ...
... Brain sees these as special events, even though result ... News) -- A near-win in gambling stimulates a large ... boosts a person,s motivation to gamble, according to British ... explain why gambling attracts so many people and why ...
Cached Medicine News:Health News:Read my lips: Using multiple senses in speech perception 2Health News:Electronic Health Record Advances Patient-Centered Cancer Care at Cancer Treatment Centers of America 2Health News:Electronic Health Record Advances Patient-Centered Cancer Care at Cancer Treatment Centers of America 3Health News:House Passes ALFA-Supported National Silver Alert Bill 2Health News:Preferred Care Partners Management Group Deploys Voice-Assisted Care 2Health News:Preferred Care Partners Management Group Deploys Voice-Assisted Care 3Health News:'Near-Wins' Boost Desire to Keep Gambling 2
... metered dose inhalers., ,ACE ensures prompt, ... canisters. Its versatile design allows it to ... conjunction with an endotracheal airway or resuscitation ... may also be used in conjunction with ...
Infant Nebulizer Kit W/Misty-Nebulizer 30/CS CE Mark Only...
... Anesthesia and Respiratory Products, ,Westmed designs, ... for Anesthesia and Respiratory professionals. Our mission ... enhance the clinician's ability to deliver quality ... the bottom line. , ,Our web ...
... metered dose inhalers., ,ACE ensures prompt, ... canisters. Its versatile design allows it to ... conjunction with an endotracheal airway or resuscitation ... may also be used in conjunction with ...
Medicine Products: